Heat Biologics (NASDAQ: HTBX) is developing novel therapies that activate a patient’s immune system against cancer. The company’s T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. In combination with other therapies, these platforms are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells; T cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Heat is conducting a phase 2 trial with its HS-410 in patients with non-muscle invasive bladder cancer (NMIBC) and a phase 1b trial with its HS-110 in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, visit the company’s website at www.heatbio.com